J. Jorgensen - Department of Hematology, Aarhus University Hospital

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Glofitamab Plus Polatuzumab Vedotin Demonstrates Durable Responses and a Manageable Safety Profile in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

S. Dietrich,M. Hutchings,A. Avigdor,A. Sureda,M. J. Terol,F. Bosch,P. Corradini,Stauffer T. Larsen,Rueda A. Dominguez,A. Skarbnik,J. Jorgensen,N. Goldschmidt,

ONCOLOGY RESEARCH AND TREATMENT (2023): 209-209

引用1浏览0引用

HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY

L Meriranta,A Alkodsi,A Pasanen,M Lepistö,Y. N Blaker,J Jørgensen, P Mapar,M Björkholm,M Jerkeman,H Holte,E Pitkänen,P Ellonen,

Hematological Oncologyno. S2 (2021)

引用0浏览0引用

FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20‐POSITIVE TUMORS, RITUXIMAB IN RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMAS

F d'Amore,S Leppä,T Relander,T. S Larsen,P Brown,J Jørgensen,S Mannisto,P Lugtenburg,S.‐K Leivonen,H Holte,U. M Fagerli,G. F Lauritzsen,

Hematological Oncologyno. S2 (2021)

引用0浏览0引用

CLINICAL SIGNIFICANCE OF T-CELL EXHAUSTION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

S. Leppä,M. Autio,O. Brück,S. Mustjoki,J. Jørgensen,M. Karjalainen-Lindsberg,K. Beiske,H. Holte,T. Pellinen, S. Leivonen

Hematological Oncology（2019）

引用0浏览0引用

YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDING BCL‐2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE‐DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS

S. Leppä,J. Jørgensen,A. Tierens,L. Meriranta,I. Østlie,P. Brown,U. Fagerli,T.S. Larsen,S. Mannisto,L. Munksgaard,M. Maisenhølder,K. Vasala,

Hematological oncology（2019）

引用0浏览0引用

Acute myeloid leukemia-Biology B1224 PROLIFERATION OF ACUTE MYELOGENOUS BLASTS AS EFFECT OF DIFFERENT CYTOKINES CAN BE USED TO IDENTIFIED PATIENT AND CYTOKINE SUBSETS ALSO BY GENE EXPRESSION PROFILES

H Reikvam,A Margrete Øyan,K Kalland,R Hovland,K Hatfield, Bruserud, D Jeyaratnam, M Hansen,J Jørgensen,H Ommen,P Hokland,C Nyvold,

semanticscholar（2014）

引用0浏览0引用

Preliminary Clinical Experience on the Efficacy and Feasibility of A New Combination Regimen Consisting of Pixantrone, Etoposide, and Bendamustine with or Without the Addition of Rituximab in Patients with Relapsed/Refractory Aggressive Non-Hodgkin Lymphomas

F. d'Amore,J. Jorgensen,I. Sillesen,E. Segel,H. Bentzen,M. Thorsgaard, E. J. Pulczinsky,B. B. Pedersen, D. Gillstroem,M. Clausen,P. Kamper,T. Silkjaer,

Blood（2014）

引用6浏览0引用

DIFFERENTIAL EXPRESSION OF NEW METNASE (SETMAR) TRANSCRIPT VARIANTS IN HEMATOLOGICAL CANCERS- INCREASE IN AML PATIENTS

D. Jeyaratnam,M. Hansen,J. Jorgensen,H. Ommen,P. Hokland,C. Nyvold

HAEMATOLOGICA（2013）

引用0浏览0引用

HIGHLY SPECIFIC QPCR ASSAYS USING A CONSENSUS LNA PROBE FOR THE DETECTION OF T(11;14) AND T(14;18) IN NON-HODGKIN LYMPHOMA WITH A SENSITIVITY OF 10-5 FOR QUANTIFICATION OF MINIMAL RESIDUAL DISEASE

C. Sorensen,J. Jorgensen,P. Hokland,C. Nyvold

HAEMATOLOGICA（2013）

引用0浏览0引用

METNASE (SETMAR) AND HPSO4 (HPRPF19) EXPRESSION IN HEMATOLOGICAL CANCERS

D. Jeyaratnam, B. Baduin,L. Ebbesen,J. Jorgensen,C. Nyvold

HAEMATOLOGICA（2012）

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn